Teachers Retirement System of The State of Kentucky Sells 1,352 Shares of Insulet Corporation (NASDAQ:PODD)

Teachers Retirement System of The State of Kentucky trimmed its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 3.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 34,702 shares of the medical instruments supplier's stock after selling 1,352 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in Insulet were worth $9,113,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Insulet by 2.3% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after buying an additional 48 shares in the last quarter. Quadrant Capital Group LLC increased its stake in shares of Insulet by 4.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier's stock valued at $285,000 after purchasing an additional 51 shares during the last quarter. OLD National Bancorp IN raised its stake in Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after acquiring an additional 55 shares in the last quarter. Syon Capital LLC lifted its stake in Insulet by 5.6% in the 4th quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock valued at $291,000 after purchasing an additional 59 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Insulet by 23.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after acquiring an additional 59 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PODD shares. Oppenheimer lifted their target price on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Truist Financial assumed coverage on shares of Insulet in a research note on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective for the company. Barclays increased their price target on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They set a "buy" rating and a $380.00 target price for the company. Finally, Sanford C. Bernstein reissued an "outperform" rating on shares of Insulet in a research report on Friday, May 16th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of "Moderate Buy" and an average target price of $321.00.

Insulet Price Performance

Insulet stock opened at $284.23 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. Insulet Corporation has a one year low of $173.00 and a one year high of $329.33. The firm has a market capitalization of $20.00 billion, a P/E ratio of 51.12, a PEG ratio of 2.54 and a beta of 1.35. The business has a fifty day moving average price of $309.07 and a 200-day moving average price of $281.16.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm's quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the company earned $0.73 earnings per share. As a group, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president directly owned 23,180 shares in the company, valued at $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.39% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.